Physician profile
David Filippi
NPI 1154347862
$21,757.67
in general payments reported to CMS, 2019-2025
37 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,186 · 2021: $378 · 2022: $16.11 · 2023: $946 · 2024: $514 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $12,309.61 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $5,101.63 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $652.61 | 2019 | |
| Emd Serono, INC. | $396.05 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $366.88 | 2019-2025 | Uplizna |
| Greenwich Biosciences, INC. | $271.38 | 2019 | |
| Horizon Therapeutics Plc | $226.66 | 2023 | Uplizna, Tepezza |
| Novartis Pharmaceuticals Corporation | $218.50 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $189.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $175.87 | 2019-2024 | Ultomiris |
| Abbott Laboratories | $159.46 | 2023 | Amplatzer Talisman |
| Mdd US Operations, LLC | $158.70 | 2019 | |
| Boston Scientific Corporation | $146.11 | 2019 | |
| Atricure, INC. | $139.88 | 2023 | |
| Ucb, INC. | $124.60 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $122.10 | 2023 | |
| Penumbra, INC. | $116.18 | 2024 | Penumbra System |
| Abbvie INC. | $102.55 | 2019-2023 | |
| Genentech USA, INC. | $87.52 | 2019 | |
| Neurocrine Biosciences, INC. | $85.16 | 2019 | |
| Adamas Pharmaceuticals, INC. | $64.84 | 2019 | |
| Acorda Therapeutics, INC | $60.72 | 2019 | |
| Lilly USA, LLC | $57.68 | 2019 | |
| Allergan, INC. | $52.58 | 2019-2020 | |
| Genzyme Corporation | $46.35 | 2019 | |
| Amneal Pharmaceuticals LLC | $41.03 | 2019 | |
| Sk Life Science, INC. | $40.15 | 2023 | |
| Supernus Pharmaceuticals, INC. | $39.63 | 2019-2023 | Qelbree |
| Csl Behring | $34.74 | 2019 | |
| Octapharma USA, INC. | $27.48 | 2023 | Panzyga |
| Pfizer INC. | $26.22 | 2023 | |
| Kyowa Kirin, INC. | $24.89 | 2019 | |
| Livanova USA, INC. | $20.58 | 2019 | |
| Argenx US, INC. | $19.35 | 2023 | Vyvgart |
| Alnylam Pharmaceuticals INC. | $19.12 | 2019 | |
| Medtronic, INC. | $16.11 | 2022 | |
| Grifols USA, LLC | $15.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Filippi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.